[Cardioprotective effect of exogenous phosphocreatine in patients undergoing open heart surgery].
Twenty patients with rheumatic heart valve disease undergoing valve replacement were randomly divided into 2 group (n = 10): phosphocratine (neoton) group (group CP) in which 4.0 g neoton was used intravenously 2 days before operation and control group (group C) in which 5% G. S instead of neoton. The results showed that spontaneous recovery rate of heart beat in group CP was significantly higher than that in group C; requirement of inotropic drugs, serum MDA value and ultrastructural changes of myocardium were less in group CP than those in group C. There were no differences in release of myocardial enzymes and myocardial ATP content between 2 groups. It is suggested that neoton is an effective cardioprotective drug.
Cheng
S X
SX
Department of Cardiothoracic Surgery, Xiangya Hospital, Central South University, Changsha 410008, China.
Hu
Q H
QH
D002315:Cardiopulmonary Bypass; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D019918:Heart Valve Prosthesis Implantation; D006801:Humans; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D010725:Phosphocreatine / Q000627:therapeutic use*; D012214:Rheumatic Heart Disease / Q000601:surgery*; D013482:Superoxide Dismutase / Q000378:metabolism
D002316:Cardiotonic Agents; D010725:Phosphocreatine; D013482:Superoxide Dismutase